Decibel Therapeutics Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Laurence Reid

Amministratore delegato

US$1.2m

Compenso totale

Percentuale dello stipendio del CEO	44.5%
Mandato del CEO	3.8yrs
Proprietà del CEO	n/a
Durata media del management	2.1yrs
Durata media del Consiglio di amministrazione	2.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation

Aug 10

Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?

Feb 07

Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial

Oct 17

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Sep 01

Decibel Therapeutics: Gene Therapies For Hearing Loss

Jul 06

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Laurence Reid rispetto agli utili di Decibel Therapeutics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2023	n/a	n/a	-US$63m
Mar 31 2023	n/a	n/a	-US$62m
Dec 31 2022	US$1m	US$548k	-US$63m
Sep 30 2022	n/a	n/a	-US$60m
Jun 30 2022	n/a	n/a	-US$60m
Mar 31 2022	n/a	n/a	-US$55m
Dec 31 2021	US$801k	US$522k	-US$54m
Sep 30 2021	n/a	n/a	US$576k
Jun 30 2021	n/a	n/a	US$7m
Mar 31 2021	n/a	n/a	US$8m
Dec 31 2020	US$4m	US$574k	US$7m

Compensazione vs Mercato: La retribuzione totale di Laurence ($USD 1.23M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 649.63K ).

Compensazione vs guadagni: La retribuzione di Laurence è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Laurence Reid (59 yo)

3.8yrs

Mandato

US$1,232,276

Compensazione

Dr. Laurence E. Reid, Ph D., serves as President, Chief Executive Officer and until September 25, 2023 served as Director at Decibel Therapeutics, Inc. since January 2020 and served as its consultant since...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Laurence Reid	President & CEO	3.8yrs	US$1.23m	Nessun dato
Anna Trask	Executive VP & Chief People Officer	5.8yrs	US$618.23k	0% $ 0
John Lee	Executive VP & Chief Development Officer	7.1yrs	US$733.16k	0% $ 0
M. Liberman	Co-Founder & Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Gabriel Corfas	Co-Founder & Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Ulrich Müller	Co-Founder & Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Albert S. Edge	Co-Founder & Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
James Murphy	Interim CFO	less than a year	Nessun dato	Nessun dato
Elaine Cope	Vice President of Operations	2.1yrs	Nessun dato	Nessun dato
Geoff Horwitz	VP of Corporate Development & Head of Business Development	less than a year	Nessun dato	Nessun dato
Vassili Valayannopoulos	VP and Head of Clinical Research & Development	less than a year	Nessun dato	Nessun dato

2.1yrs

Durata media

65yo

Età media

Gestione esperta: Il team dirigenziale di DBTX è considerato esperto (durata media dell'incarico 2.1 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
M. Liberman	Co-Founder & Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Gabriel Corfas	Co-Founder & Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Ulrich Müller	Co-Founder & Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Albert S. Edge	Co-Founder & Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Glenn Pierce	Member of Scientific Advisory Board	2.4yrs	Nessun dato	Nessun dato
Constance Cepko	Member of Scientific Advisory Board	2.4yrs	Nessun dato	Nessun dato
Guangping Gao	Member of Scientific Advisory Board	2.4yrs	Nessun dato	Nessun dato
Alan Cheng	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
David Ginty	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Michael Greenberg	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Dwight Bergles	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Matthew Kelley	Member of Scientific Advisory Board	2.4yrs	Nessun dato	Nessun dato

2.4yrs

Durata media

68yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di DBTX non è considerato esperto (durata media del mandato 2.4 anni), il che suggerisce un nuovo consiglio.

Decibel Therapeutics Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Decibel Therapeutics, Inc. Announces Board Changes

High number of new directors

High number of new directors

Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors

Decibel Therapeutics, Inc. Announces Executive Changes

Decibel Therapeutics, Inc., Annual General Meeting, Jun 17, 2022

Recent updates

Decibel Therapeutics, Inc. Files Form 15

New major risk - Revenue and earnings growth

Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from NASDAQ Composite Index

Decibel Therapeutics, Inc. Announces Board Changes

Decibel Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation for DB-OTO

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) entered into a definitive agreement to acquire remaining unknown majority stake in Decibel Therapeutics, Inc. (NasdaqGS:DBTX) from a group of shareholders for approximately $100 million.

Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation

Price target increased by 13% to US$15.33

Consensus EPS estimates upgraded to US$1.89 loss

Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices to Initiate Clinical Development of Lead Gene Therapy Candidate Db-OTO

Price target decreased by 7.4% to US$12.60

Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?

PDecibel Therapeutics, Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO

Consensus revenue estimates fall by 25%

High number of new directors

Decibel Therapeutics, Inc. Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate Db-Oto

High number of new directors

Price target decreased to US$14.60

Decibel Therapeutics, Inc. Receives Fda Clearance of Ind Application for Db-Oto, A Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss

Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial

Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors

Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO

Decibel Therapeutics, Inc. Announces Executive Changes

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Price target decreased to US$15.40

Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy

Price target decreased to US$14.75

Consensus forecasts updated

Decibel Therapeutics, Inc., Annual General Meeting, Jun 17, 2022

Price target decreased to US$17.00

Less than half of directors are independent

Price target decreased to US$21.33

Decibel Therapeutics Announces the Presentation of Preclinical Data on Lead Gene Therapy Product Candidate, DB-OTO and Preclinical Data Highlighting the Identification of Proprietary

Less than half of directors are independent

Chief People notifies of intention to sell stock

President recently bought US$76k worth of stock

Vice President of Finance & Principal Accounting Officer Ronald Vigliotta has left the company

Investor sentiment improved over the past week

Consensus revenue estimates fall to US$2.08m

Investor sentiment deteriorated over the past week

Decibel Therapeutics: Gene Therapies For Hearing Loss

Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from Russell Microcap Growth Index

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Decibel Therapeutics, Inc. Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations

Decibel Therapeutics, Inc. has completed an IPO in the amount of $127.116 million.

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media